Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Equity Ratio (2021 - 2025)

ARS Pharmaceuticals' Equity Ratio history spans 5 years, with the latest figure at 0.35 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 52.32% year-over-year to 0.35; the TTM value through Dec 2025 reached 0.35, down 52.32%, while the annual FY2025 figure was 0.35, 52.32% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.35 at ARS Pharmaceuticals, down from 0.4 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.99 in Q4 2023 and bottomed at 0.51 in Q4 2021.
  • The 5-year median for Equity Ratio is 0.93 (2021), against an average of 0.62.
  • The largest annual shift saw Equity Ratio tumbled 119.64% in 2022 before it soared 886.58% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.51 in 2021, then surged by 290.54% to 0.97 in 2022, then grew by 2.06% to 0.99 in 2023, then dropped by 26.1% to 0.73 in 2024, then tumbled by 52.32% to 0.35 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Equity Ratio are 0.35 (Q4 2025), 0.4 (Q3 2025), and 0.61 (Q2 2025).